ロード中...
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
BACKGROUND: In clinical practice the gold standard method to assess BRAF status in patients with metastatic melanoma is based on molecular assays. Recently, a mutation-specific monoclonal antibody (VE1), which detects the BRAF V600E mutated protein, has been developed. With this study we aimed to co...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5116153/ https://ncbi.nlm.nih.gov/pubmed/27863476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2951-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|